Recap: Accelerate Diagnostics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Accelerate Diagnostics (NASDAQ:AXDX) reported Q4 earnings with an EPS of $-0.89, missing estimates by -44.0%. Revenue increased by $55 thousand from the previous year. The company has a history of missing EPS estimates, which previously led to a 3.0% drop in share price.
March 28, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Accelerate Diagnostics reported a significant miss in Q4 earnings with an EPS of -$0.89 against an estimate of -$0.62, and a slight increase in revenue.
Given the history of share price drops following missed earnings reports, the significant miss in Q4 earnings is likely to negatively impact AXDX's stock price in the short term. The slight increase in revenue may not be sufficient to offset the negative sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100